Fig. 1: Serum neutralising antibody titres to SARS-CoV-2 variants of concern following dose 6 of COVID-19 vaccine. | npj Vaccines

Fig. 1: Serum neutralising antibody titres to SARS-CoV-2 variants of concern following dose 6 of COVID-19 vaccine.

From: Age-associated defect in ADCC response to COVID-19 vaccine

Fig. 1

A Top, Study design. Schematic of vaccine timeline highlighting the sixth dose. Fifty-one individuals vaccinated against SARS-CoV-2 with mRNA-based vaccines and/or AZD1222 and/or sub-unit vaccine. B Schematic design of pseudovirus neutralization assay. C Neutralization titers (pNT50) stratified by age against Wu-1 D614G WT, BA.1, BA.2, XBB1.5, BA.2.86, and JN.1. D pNT50 stratified by vaccine-type at dose 6. E pNT50 stratified by sex. Multiple Mann-Whitney compare rank tests with Holm-Šídák corrections were performed to determine significance. *p < 0.05, **p < 0.005, ***p < 0.0005. NS, not significant.

Back to article page